TY  - JOUR
AU  - Sternberg, Cora N
AU  - Loriot, Yohann
AU  - James, Nicholas
AU  - Choy, Ernest
AU  - Castellano, Daniel
AU  - Lopez-Rios, Fernando
AU  - Banna, Giuseppe L
AU  - De Giorgi, Ugo
AU  - Masini, Cristina
AU  - Bamias, Aristotelis
AU  - Garcia Del Muro, Xavier
AU  - Duran, Ignacio
AU  - Powles, Thomas
AU  - Gamulin, Marija
AU  - Zengerling, Friedemann
AU  - Geczi, Lajos
AU  - Gedye, Craig
AU  - de Ducla, Sabine
AU  - Fear, Simon
AU  - Merseburger, Axel S
PY  - 2019
DO  - 10.1016/j.eururo.2019.03.015
UR  - http://hdl.handle.net/10668/13756
T2  - European urology
AB  - Atezolizumab, a humanised monoclonal antibody targeting PD-L1, is approved for locally advanced/metastatic urothelial carcinoma. SAUL evaluated atezolizumab in a broader, pretreated population, including patients ineligible for the pivotal IMvigor211...
LA  - en
KW  - Atezolizumab
KW  - Autoimmune disease
KW  - Central nervous system metastases
KW  - Immunotherapy
KW  - Nonurothelial carcinoma
KW  - PD-L1
KW  - Real world
KW  - Steroid
KW  - Urothelial carcinoma
KW  - Aged
KW  - Anemia
KW  - Anorexia
KW  - Antibodies, Monoclonal, Humanized
KW  - Antineoplastic Agents, Immunological
KW  - Asthenia
KW  - Carcinoma, Transitional Cell
KW  - Colitis
KW  - Disease Progression
KW  - Fatigue
KW  - Female
KW  - Humans
KW  - Hypertension
KW  - Male
KW  - Middle Aged
KW  - Progression-Free Survival
KW  - Retreatment
KW  - Survival Rate
KW  - Urinary Tract Infections
KW  - Urologic Neoplasms
TI  - Primary Results from SAUL, a Multinational Single-arm Safety Study of Atezolizumab Therapy for Locally Advanced or Metastatic Urothelial or Nonurothelial Carcinoma of the Urinary Tract.
TY  - research article
VL  - 76
ER  -